{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:50:21Z","timestamp":1791298221935,"version":"4.1.0"},"reference-count":27,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K08623"],"award-info":[{"award-number":["JP22K08623"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Association for Lower Limb Artery Revascularization"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Diabetes-related burden, including longer diabetes duration and advanced complications, substantially influences management strategies and healthcare utilization among patients with diabetes. It remains unclear whether this burden is comparable between patients with lower extremity artery disease (LEAD) and those with coronary artery disease (CAD), which are both commonly grouped as manifestations of cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare diabetes-related burden between patients with diabetes undergoing revascularization for LEAD and those undergoing revascularization for CAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study analyzed 5808 patients with diabetes undergoing revascularization for LEAD or CAD, who were registered in a prospective multicenter study. Diabetes duration, glycated hemoglobin levels, and the presence of advanced diabetes-related complications were assessed at the time of index revascularization and compared cross-sectionally between the LEAD and CAD groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The LEAD group exhibited a longer diabetes duration and a higher prevalence of advanced complications, whereas glycated hemoglobin levels at revascularization did not significantly differ between the groups. The prevalence of advanced complications remained higher in the LEAD group after adjustment for diabetes duration. The adjusted prevalence ratios of LEAD relative to CAD were 1.57 (95% confidence interval, 1.41-1.75, P &amp;lt; .001) for proliferative retinopathy, 2.39 (1.82-3.13, P &amp;lt; .001) for loss of protective sensation, and 2.12 (1.82-2.48, P &amp;lt; .001) for dialysis-dependent renal failure, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients undergoing revascularization for LEAD exhibited a longer diabetes duration than those undergoing revascularization for CAD. They also had a higher prevalence of advanced diabetes-related complications, even after adjustment for diabetes duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag387","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:01:50Z","timestamp":1790164910000},"source":"Crossref","is-referenced-by-count":0,"title":["Diabetes duration and advanced diabetes-related complications in lower-extremity vs coronary revascularization"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-041X","authenticated-orcid":false,"given":"Mitsuyoshi","family":"Takahara","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The University of Osaka Graduate School of Medicine , Suita City, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1931-5769","authenticated-orcid":false,"given":"Yoshimitsu","family":"Soga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kokura Memorial Hospital , Kitakyushu City 802-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-7304","authenticated-orcid":false,"given":"Osamu","family":"Iida","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Keisatsu Hospital , Osaka City, Osaka 543-0035 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"Supplement_1","key":"2026100609512728500_dgag387-B1","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.2337\/dc26-S006","article-title":"6. Glycemic goals, hypoglycemia, and hyperglycemic crises: standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"2026100609512728500_dgag387-B2","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"2026100609512728500_dgag387-B3","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.2337\/dc26-S005","article-title":"5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"issue":"11","key":"2026100609512728500_dgag387-B4","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"2026100609512728500_dgag387-B5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s13300-022-01212-4","article-title":"The association between HbA1c and 1-year diabetes-related medical costs: a retrospective claims database analysis","volume":"13","author":"Boye","year":"2022","journal-title":"Diabetes Ther"},{"issue":"12","key":"2026100609512728500_dgag387-B6","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2337\/dc08-1375","article-title":"Nationally representative medical costs of diabetes by time since diagnosis","volume":"31","author":"Trogdon","year":"2008","journal-title":"Diabetes Care"},{"issue":"8","key":"2026100609512728500_dgag387-B7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3346\/jkms.2012.27.8.876","article-title":"Direct medical costs for patients with type 2 diabetes and related complications: a prospective cohort study based on the Korean National Diabetes Program","volume":"27","author":"Kim","year":"2012","journal-title":"J Korean Med Sci"},{"issue":"6","key":"2026100609512728500_dgag387-B8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038877","article-title":"Hba1c measured in stored erythrocytes is positively linearly associated with mortality in individuals with diabetes mellitus","volume":"7","author":"Sluik","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"2026100609512728500_dgag387-B9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1046\/j.1365-2362.2002.01090.x","article-title":"Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn study","volume":"32","author":"Spijkerman","year":"2002","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2026100609512728500_dgag387-B10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12933-019-0961-7","article-title":"Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study","volume":"18","author":"Garofolo","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2026100609512728500_dgag387-B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112356","article-title":"Microvascular diseases predict mortality and cardiovascular events in type 2 diabetes: a retrospective cohort study","volume":"226","author":"Huang","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2026100609512728500_dgag387-B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ahj.2005.09.015","article-title":"Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials","volume":"152","author":"Stettler","year":"2006","journal-title":"Am Heart J"},{"issue":"7","key":"2026100609512728500_dgag387-B13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00125-009-1352-5","article-title":"Megatrials in type 2 diabetes. From excitement to frustration?","volume":"52","author":"Del Prato","year":"2009","journal-title":"Diabetologia"},{"issue":"4","key":"2026100609512728500_dgag387-B14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2337\/dc07-2124","article-title":"Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects","volume":"31","author":"Juutilainen","year":"2008","journal-title":"Diabetes Care"},{"issue":"9","key":"2026100609512728500_dgag387-B15","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2337\/diacare.20.9.1388","article-title":"NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham study","volume":"20","author":"Elias","year":"1997","journal-title":"Diabetes Care"},{"issue":"10022","key":"2026100609512728500_dgag387-B16","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"2026100609512728500_dgag387-B17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2003.12.016","article-title":"Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control","volume":"113","author":"Watala","year":"2004","journal-title":"Thromb Res"},{"issue":"9","key":"2026100609512728500_dgag387-B18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","article-title":"A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure","volume":"104","author":"Park","year":"2009","journal-title":"Am J Cardiol"},{"issue":"3","key":"2026100609512728500_dgag387-B19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"2026100609512728500_dgag387-B20","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2337\/dc12-0862","article-title":"Health care costs in people with diabetes and their association with glycemic control and kidney function","volume":"36","author":"McBrien","year":"2013","journal-title":"Diabetes Care"},{"issue":"19","key":"2026100609512728500_dgag387-B21","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"issue":"2","key":"2026100609512728500_dgag387-B22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026100609512728500_dgag387-B23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12933-019-0955-5","article-title":"Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases","volume":"18","author":"Takahara","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"Supplement_1","key":"2026100609512728500_dgag387-B24","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc26-S010","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"issue":"39","key":"2026100609512728500_dgag387-B25","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)","volume":"34","author":"Authors\/Task Force Members","year":"2013","journal-title":"Eur Heart J"},{"key":"2026100609512728500_dgag387-B26","author":"European Medicines Agency"},{"issue":"3","key":"2026100609512728500_dgag387-B27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/dom.12129","article-title":"Treat-to-target trials: uses, interpretation and review of concepts","volume":"16","author":"Garber","year":"2014","journal-title":"Diabetes Obes Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag387\/71395106\/dgag387.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag387\/71395106\/dgag387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:51:34Z","timestamp":1791294694000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag387\/8835664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag387","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"dgag387"}}